Liberate Bio integrates Quantum-Si’s next-generation protein sequencing platform to enhance gene therapy development Page 1

Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si”, “QSI” or the “Company”), The Protein Sequencing Company, today announced that Liberate Bio, a Boston-based biotech company unleashing the potential of genetic medicine with novel delivery vehicles, has integrated the Platinum Next-Generation Protein Sequencer (“NGPS”) into its platform for the development of novel gene therapies with enhanced targeting capabilities. Liberate is using the sequencer’s protein barcoding application to screen delivery vehicles for lipid nanoparticles in the fleshwith a simple readout of delivery and translation efficiency, significantly increasing the precision, speed and efficiency of their gene therapy discovery and development efforts.

Platinum provides advanced insights into the proteome, offering characterization of protein sequence and variation, at single amino acid resolution. Quantum-Si’s protein barcoding application enables researchers to simultaneously tag, track, select, and measure a set of target proteins, using both in vitro And in the flesh screening applications. And unlike alternative approaches such as mass spectrometry, it does not require expensive equipment or specialized expertise.